Robert Avery, MD
Retina Specialist · Santa Barbara, CANPI 1700985496
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Genentech USA, Inc. at 35.1% of the total. Reporting peaked in 2022 at $69,465 and has fallen 80.9% since, to $13,248 in 2025. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $536.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$63K
- Genentech, Inc.$21K
- Coherus Oncology, Inc.$14K
- Bausch & Lomb Americas Inc.$13K
- AbbVie$13K
- Ocular Therapeutix, Inc.$12K
- plus $44K from 26 others
Across 23 payments — averaging $1135.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$16K
- Genentech, Inc.$10K
- AbbVie$263
What the payments were for
- Consulting fees$91,95251%
- Speaking & faculty fees$51,56529%
- Travel & lodging$12,3277%
- Food & beverage$15,1418%
- Ownership interest$9,2835%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 72 | $63,186 |
| Genentech, Inc. | 17 | $21,269 |
| Coherus Oncology, Inc. | 10 | $14,436 |
| Bausch & Lomb Americas Inc. | 19 | $12,809 |
| AbbVie(2 entities) | 44 | $12,620 |
| Ocular Therapeutix, Inc. | 18 | $11,696 |
| Alcon Research LLC | 3 | $10,187 |
| US Retina LLC | 5 | $9,283 |
| Regeneron Healthcare Solutions, Inc. | 41 | $6,265 |
| Apellis Pharmaceuticals, Inc. | 28 | $3,929 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $3,234 |
| F. Hoffmann-la Roche AG | 1 | $2,250 |
| Oyster Point Pharma, Inc. | 2 | $2,142 |
| Eyepoint US, Inc. | 4 | $1,947 |
| Alcon | 14 | $1,734 |
| Astellas Pharma US Inc | 16 | $774 |
| Regeneron | 8 | $607 |
| Harrow Eye, LLC | 7 | $439 |
| Novartis | 4 | $272 |
| Sight Sciences, Inc. | 2 | $240 |
| Alimera Sciences, Inc. | 4 | $179 |
| Biogen | 2 | $150 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $123 |
| Dompe US, Inc. | 1 | $111 |
| Dutch Ophthalmic, USA | 1 | $107 |
| Neurotech Pharmaceuticals, Inc. | 1 | $101 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Glaukos Corporation | 1 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| GSK | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$180,268 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 26 | $1,019 |
| Ketorolac Tromethamine | 17 | $877 |
| Latanoprost | 34 | $571 |
| ErythromycinErythromycin Base | 30 | $341 |
| Timolol Maleate | 16 | $170 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Santa Barbara
- Dilsher DhootSanta Barbara$1.9M
- Nathan SteinleSanta Barbara$1.1M
- Dante PieramiciSanta Barbara$267K
- Nika BagheriSanta Barbara$73K
- Daniel LearnedSanta Barbara$49K
- Stephen CouvillionSanta Barbara$43K
- Alessandro CastellarinSanta Barbara$24K
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Roger GoldbergWalnut Creek$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.